×
About 173,520 results

Expert Perspective on ASCO20 Lung Cancer Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200235/full/

Top Lung Cancer Research Presented at the ASCO20 Virtual Scientific Program Has Implications for Clinical Practice
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200223/full/

Jun 24th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented d...

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
https://ascopost.com/news/may-2020/first-line-pembrolizumab-plus-etoposideplatinum-for-extensive-stage-small-cell-lung-cancer/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-stage small cel...

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 28th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Never Too Late: Smoking Cessation Just Before Lung Cancer Diagnosis Leads to Survival Benefit
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200126/full/

May 12th, 2020 - A retrospective study examining the time since a patient quit smoking before a lung cancer diagnosis and the subsequent survival outcomes after the lung cancer diagnosis indicated that it is never too late to stop smoking (Abstract 1512). Among patients diagnosed with lung cancer who had quit smoking within 2 years of lung cancer diagnosis...

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer
https://www.onclive.com/conference-coverage/asco-2020/frontline-durvalumab-maintains-os-benefit-in-updated-essclc-findings

May 29th, 2020 - The addition of durvalumab (Imfinzi) to standard chemotherapy continued to demonstrate an improvement in overall survival (OS) for patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), according to updated results from the phase 3 CASPIAN study presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Bladder Cancer Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq?cid=eb_govdel

Bladder cancer is the sixth most common cancer in the United States after lung cancer, prostate cancer, breast cancer, colon cancer, and lymphoma. It is the third most common cancer in men and the eleventh most common cancer in women. Of the roughly 70,000 new cases annually, about 53,000 are in men and about 18,000 are in women. Of...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 23rd, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

Top 20 Research Studies of 2019 for Primary Care Physicians
https://www.aafp.org/afp/2020/0515/p608.html

In 2019, regular surveillance of 110 English-language research journals identified 254 studies that met the criteria to become POEMs (patient-oriented evidence that matters). Physician members of the Canadian Medical Association rated these POEMs for their relevance to patients in their practices. This article summarizes the clinical questions and bottom-line answers from the top 20 POEMs of 20...

Adjuvant Osimertinib ‘Exceeds Expectations’ in Early-Stage EGFR-Positive NSCLC
https://ascopost.com/news/may-2020/adjuvant-osimertinib-exceeds-expectations-in-egfr-positive-nsclc/

May 27th, 2020 - Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA ­EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. These results from the first interim analysis of the phase III ADAURA trial were reported at the ASCO20 Virtual Scientific...

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage Ib–IIIa EGFR Mutation–Positive Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/roy-herbst-on-osimertinib-in-stage-ib-iiia-egfr-mutation-positive-nsclc/

May 29th, 2020 - Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).

ADJUVANT-CTONG 1104 Results Underscore the Value of Using EGFR-Targeted Therapy in EGFR-Mutated NSCLC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200182/full/

May 28th, 2020 - During the 2017 ASCO Annual Meeting, investigators of the ADJUVANT-CTONG 1104 trial first reported that postsurgical treatment with gefitinib conferred a significant 10.7-month improvement in disease-free survival (DFS) compared with standard doublet chemotherapy in patients with stage II-IIIA EGFR-positive non–small cell lung cancer (NSCLC), thus meeting the primary study endpoin...

Upfront Radiation Added to TKI Therapy Improves Outcomes in Oligometastatic NSCLC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200171/full/

May 28th, 2020 - The addition of stereotactic body radiation therapy (SBRT) to tyrosine kinase inhibitor (TKI) therapy yielded longer progression-free survival (PFS) and overall survival (OS) than TKI therapy alone in patients with EGFR-mutant oligometastatic non–small cell lung cancer (NSCLC), according to an interim analysis of an open-label phase III trial presented during the ASCO20 Virtual Sc...

Dr. Pasi A. Jänne Honored With the Science of Oncology Award
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200139/full/

May 12th, 2020 - Pasi A. Jänne, MD, PhD, professor of medicine at Harvard Medical School, director of the Chen-Huang Center for EGFR-Mutant Lung Cancers, and director of the Belfer Center for Applied Cancer Sciences at Dana-Farber Cancer Institute, has been named the 2020 Science of Oncology Award recipient for his career-long contributions to advancing therapies for lung c...

First-line nivolumab plus platinum/etoposide effective in extensive-stage SCLC
https://www.mdedge.com/hematology-oncology/article/223035/lung-cancer/first-line-nivolumab-plus-platinum/etoposide

May 29th, 2020 - While nivolumab plus doublet chemotherapy was effective in extensive-stage small-cell lung cancer (ES-SCLC) in a recent randomized trial, the results might not be sufficient to change current clinical practice, in which two first-line chemo-immunotherapies are already approved and recommended, sources said.

Adjuvant osimertinib extends DFS in localized NSCLC
https://www.mdedge.com/hematology-oncology/article/222909/lung-cancer/adjuvant-osimertinib-extends-dfs-localized-nsclc

May 27th, 2020 - Adjuvant therapy with osimertinib was associated with a nearly 80% reduction in the risk of disease recurrence or death in patients with stage IB-IIIA non–small cell lung cancer (NSCLC) bearing EGFR mutations, results of the ADAURA trial showed.

Adjuvant osimertinib extends DFS in EGFR-mutated NSCLC
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{641f2259-d903-472a-acbb-681a7bbd3eec}/adjuvant-osimertinib-extends-dfs-in-egfr--mutated-nsclc

May 28th, 2020 - Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

Trastuzumab deruxtecan proves active in HER2-mutated NSCLC
https://www.mdedge.com/hematology-oncology/article/223050/lung-cancer/trastuzumab-deruxtecan-proves-active-her2-mutated

May 30th, 2020 - Among patients with HER2-mutated non–small-cell lung cancer (NSCLC) in an ongoing phase 2 trial, treatment with trastuzumab deruxtecan (T-DXd) has yielded a high response rate, and the median duration of response has not yet been reached, an investigator reported.

Durable Responses Elicited with Nivolumab Plus Ipilimumab in Advanced NSCLC
https://www.targetedonc.com/view/durable-responses-elicited-with-nivolumab-plus-ipilimumab-in-advanced-nsclc

May 28th, 2020 - Frontline treatment with the combination of with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced durable and long-term efficacy benefits in patients with advanced non-small cell lung cancer (NSCLC) and tumor PD-L1 expression of at least 1% or less than 1%, according to updated results from part 1 of the phase 3 Checkmate 227 trial presented at the 2020 ASCO Virtual Scientific ...

Trastuzumab Deruxtecan Demonstrates Favorable Clinical Activity in HER2+ NSCLC
https://www.targetedonc.com/view/trastuzumab-deruxtecan-demonstrates-favorable-clinical-activity-in-her2-nsclc

May 28th, 2020 - As treatment of HER2-mutated non–small cell lung cancer (NSCLC in the phase 2 DESTINY-Lung01 trial, Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated favorable clinical activity with a high objective response rate (ORR) and durable responses, according to data reported during the 2020 ASCO Virtual Scientific Meeting.